Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology, Inc. filed a current report to note that it has posted an updated presentation about its business on its website. The slide deck, filed as Exhibit 99.1 and incorporated by reference, is intended to provide summary information alongside the company’s other SEC filings and public announcements. The company states that the presentation speaks only as of the report date and that it does not undertake an obligation to update it. The materials contain forward-looking statements, and investors are cautioned not to place undue reliance on those statements.
MAIA Biotechnology filed an 8-K to share that it issued a press release announcing positive efficacy data from its THIO-101 Phase 2 clinical trial in non-small cell lung cancer. This suggests the company is seeing encouraging signals from THIO-101 in a difficult-to-treat cancer setting, although detailed results are contained in the attached press release rather than this summary document.
The company also includes standard cautionary language that these are forward-looking statements and that actual outcomes may differ due to clinical, regulatory, manufacturing, market acceptance, and intellectual property risks. No financial figures or commercial timelines are discussed in this filing.
MAIA Biotechnology, Inc. filed a current report describing new clinical data communication activities. The company prepared a scientific poster showing efficacy data from its Phase 2 THIO-101 trial, which evaluates THIO given in sequence with the immune checkpoint inhibitor cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer who had already failed two or more standard-of-care treatments.
The poster was selected as an abstract titled “Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS” and was presented at the 2025 IASLC World Conference on Lung Cancer on September 7, 2025. MAIA plans to post the same poster on its website on September 8, 2025 and has filed it as Exhibit 99.1 to this report. The company notes that the poster includes forward-looking statements and cautions investors not to place undue reliance on them.
MAIA Biotechnology reported that the European Patent Office has decided to grant a patent that broadly covers a portfolio of ateganosine-based analogues directed to telomere-targeting anticancer therapy. The patent also covers methods of using ateganosine (THIO) either alone or prior to administration of checkpoint inhibitors (CPIs). The filing attaches a press release as Exhibit 99.1 which is incorporated by reference.
The filing contains the Companys standard forward-looking statements cautioning that future results are subject to risks and uncertainties, including the initiation, timing, cost, progress and results of preclinical and clinical studies, regulatory filings and approvals, manufacturing and commercialization, market acceptance, and intellectual property protection. No financial results or transaction terms are disclosed in this report.
MAIA Biotechnology, Inc. reported unaudited condensed consolidated results for the quarter ended June 30, 2025. The company held $10,144,522 in cash and reported total assets of $11,045,854 and total liabilities of $7,169,170, leaving stockholders' equity of $3,876,684. The company had 31,818,480 shares issued and outstanding at June 30, 2025 and 32,993,220 shares outstanding as of August 11, 2025.
Operating expenses for the quarter were $5.17 million (R&D $3.11M; G&A $2.06M). Net loss was $5.35 million in the quarter and $9.86 million for the six months, narrower than the prior-year six-month loss of $16.95M; basic and diluted loss per share was $0.34 for the six months. Net cash used in operating activities for six months was $8.34 million; net cash provided by financing activities was $8.87 million from ATM sales and multiple private placements.
The filing discloses substantial doubt about the company’s ability to continue as a going concern within one year, noting an accumulated deficit of $97,099,055 and that additional equity or debt financing will be required.